Accessibility Menu
 
Ascendis Pharma A/s logo

Ascendis Pharma A/s

(NASDAQ) ASND

Current Price$220.05
Market Cap$13.53B
Since IPO (2015)+1,071%
5 Year+70%
1 Year+57%
1 Month-8%

Ascendis Pharma A/s Financials at a Glance

Market Cap

$13.53B

Revenue (TTM)

$717.81M

Net Income (TTM)

$227.72M

EPS (TTM)

$-4.20

P/E Ratio

-52.53

Dividend

$0.00

Beta (Volatility)

0.71 (Low)

Price

$220.05

Volume

32,928

Open

$224.57

Previous Close

$220.05

Daily Range

$219.02 - $224.57

52-Week Range

$124.06 - $248.60

ASND: Motley Fool Moneyball Superscore

68

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Ascendis Pharma A/s

Industry

Biotechnology

CEO

Jan Møller Mikkelsen

Headquarters

Hellerup, 2900, DK

ASND Financials

Key Financial Metrics (TTM)

Gross Margin

86%

Operating Margin

-19%

Net Income Margin

-32%

Return on Equity

0%

Return on Capital

-59%

Return on Assets

-17%

Earnings Yield

-1.90%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$13.53B

Shares Outstanding

61.38M

Volume

32.93K

Short Interest

0.00%

Avg. Volume

677.41K

Financials (TTM)

Gross Profit

$588.53M

Operating Income

$130.89M

EBITDA

$113.90M

Operating Cash Flow

$51.77M

Capital Expenditure

$8.15M

Free Cash Flow

$43.62M

Cash & ST Invst.

$615.78M

Total Debt

$871.41M

Ascendis Pharma A/s Performance Analysis

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q4 2025YOY CHG

Revenue

$245.18M

+41.0%

Gross Profit

$217.98M

+36.3%

Gross Margin

88.91%

N/A

Market Cap

$13.53B

N/A

Market Cap/Employee

$13.31M

N/A

Employees

1,017

N/A

Net Income

$33.25M

+13.6%

EBITDA

$14.58M

+138.5%

Quarterly Fundamentals

Name
Q4 2025YOY CHG

Net Cash

$255.64M

+13.9%

Accounts Receivable

$157.63M

-5.2%

Inventory

$301.40M

+2.0%

Long Term Debt

$385.09M

+5.5%

Short Term Debt

$486.32M

-1.1%

Return on Assets

-17.49%

N/A

Return on Invested Capital

-58.50%

N/A

Free Cash Flow

$67.37M

+176.9%

Operating Cash Flow

$70.67M

+181.1%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
BBIOBridgeBio Pharma, Inc.
$71.93-0.48%
SMMTSummit Therapeutics Inc.
$19.22+2.84%
GHGuardant Health, Inc.
$93.30+4.06%
IONSIonis Pharmaceuticals, Inc.
$73.89-0.59%

Trending Stocks

Symbol / CompanyPricePrice Chg
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares
$10.49-0.03%
TQQQProShares Trust - ProShares UltraPro Qqq
$44.15+0.00%
NVDGraniteShares ETF Trust - GraniteShares 2x ShortDA Daily ETF
$7.25-0.01%
SKYQSky Quarry
$6.36+0.27%

Questions About ASND

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.